Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Biocon Limited
  6. News
  7. Summary
    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biocon Limited Announces Revenue Guidance for the Full Financial Year 2022

10/21/2021 | 02:11pm EST

Biocon Limited announced revenue guidance for the full financial year 2022. For the period, the company anticipates mid-teens revenue growth.


ę S&P Capital IQ 2021
All news about BIOCON LIMITED
01/21Biocon Ltd announced its consolidated financial results for the third quarter ended Dec..
AQ
01/21Biocon's Consolidated Profit Climbs in Fiscal Q3
MT
2021Biocon Biologics Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus..
AQ
2021Biocon Ltd. - Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post..
AQ
2021Biocon Unit's US Partner Begins Clinical Study in India of Antibody Itolizumab
MT
2021Indian shares end higher buoyed by consumer and metal stocks
RE
2021India's Biocon in talks with Mylan to merge biosimilar businesses - Moneycontrol
RE
2021Biocon Reportedly in Talks with Mylan to Merge Biosimilar Businesses
CI
2021Biocon Partners with Tabuk Pharmaceutical for Middle Eastern Expansion
MT
2021Biocon Limited Announces Partnership with Tabuk Pharmaceutical Manufacturing
CI
More news
Financials
Sales 2022 80 326 M 1 071 M 1 071 M
Net income 2022 6 665 M 88,8 M 88,8 M
Net Debt 2022 29 454 M 393 M 393 M
P/E ratio 2022 65,7x
Yield 2022 0,33%
Capitalization 433 B 5 774 M 5 772 M
EV / Sales 2022 5,76x
EV / Sales 2023 4,51x
Nbr of Employees 13 500
Free-Float 34,2%
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | BIOCON | INE376G01013 | MarketScreener
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 364,10 INR
Average target price 399,22 INR
Spread / Average Target 9,65%
EPS Revisions
Managers and Directors
Siddharth Mittal Chief Executive Officer, Director & MD
Indranil Sen Chief Financial Officer
Kiran Mazumdar-Shaw Executive Chairman
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOCON LIMITED-1.44%5 683
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-11.62%47 040
BIONTECH SE-40.05%37 325